Iridex (IRIX) delivered earnings and revenue surprises of -33.33% and 1.32%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?

IRIDEX has plenty of cash following a $10M strategic investment and the company is drastically cutting S&M spend. Click here to read why IRIX is a Strong Buy.

IRIDEX Corporation (NASDAQ: IRIX) is a provider of innovative ophthalmic laser-based medical products for the treatment of glaucoma and retinal diseases. Despite its current small market cap ...